Wolfe Research Rates Roivant Sciences (ROIV) Peer Perform

Wolfe Research has downgraded Roivant Sciences Ltd. (NasdaqGS: ROIV) to a Peer Perform rating on October 12, 2026. This decision comes as the biotech sector faces challenges, impacting investor sentiment and outlook. The firm did not provide a new price target with this rating change.

Other Institutional Activity in Roivant Sciences

FMR, LLC holds 81,020,390 shares of Roivant Sciences, having increased its stake by 3,041,189 shares, valued at approximately $2.72 billion. Blackrock Inc. also added to its position, growing its holdings by 3,982,797 shares to a total of 48,236,091 shares worth about $1.62 billion. In contrast, Morgan Stanley reduced its stake by 9,235,891 shares, leaving it with 42,592,905 shares valued at around $1.43 billion. QVT Financial LP trimmed its holdings by 1,439,287 shares, ending with 23,723,074 shares worth about $795 million. Vanguard Capital Management LLC increased its stake by 1,443,447 shares, totaling 22,123,198 shares valued at approximately $741 million.

Roivant Sciences Ltd. Stock Down 2.1%

Roivant shares were recently trading around $33.33 as of October 16, 2026. The stock's performance is under scrutiny, especially after the downgrade from Wolfe Research. The price reflects the ongoing volatility in the biotech industry where Roivant operates.

Recent Earnings

Roivant reported trailing twelve-month revenue of $7.53 million, but the company has faced a significant revenue decline of 33.5% year-over-year. The next earnings report is scheduled for November 9, 2026, which will provide further insights into its financial health.

Insider Buying and Selling at Roivant Sciences Ltd.

Recent insider transactions include Keith Manchester, who sold 800,000 shares on June 29, 2026, for about $27.64 million at an average price of $34.55. Additionally, QVT Financial LP and Gold Daniel Allen each sold 12,380 shares on June 30, 2026, for approximately $436,766.4 at an average price of $35.28. Keith Manchester sold another 200,000 shares on the same day for about $7.09 million.

Analysts Set New Price Targets

On October 12, 2026, Wolfe Research downgraded its rating on Roivant to Peer Perform, with no new price target set. In contrast, other analysts have maintained their Buy ratings with varying price targets; HC Wainwright & Co. set a target of $47.00, TD Cowen set a target of $55.00, and Guggenheim set a target of $46.00. The consensus among analysts remains cautiously optimistic about Roivant's potential.

About Roivant Sciences

Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company based in London, UK. It focuses on discovering, developing, and commercializing innovative medicines and technologies. The downgrade from Wolfe Research highlights the difficulties the company faces in a competitive market.

Bottom Line

Investors will be watching closely as Roivant prepares for its next earnings report on November 9, 2026. The recent downgrade from Wolfe Research adds to the scrutiny over its performance amid a challenging biotech environment.